Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers

Cancers

Ju Hye Jeong¹  Jaetae Lee²  Chae Moon Hong²  Byeong-Cheol Ahn²  Prakash Gangadaran²  Ji Min Oh²  Ramya Lakshmi Rajendran² 

[1] Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu 41944, Korea;Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea;

关键词: thyroid cancer;    GLI1;    redifferentiation;    sodium iodide symporter;    radioactive-iodine therapy;   

DOI  :  10.3390/cancers14071782

来源: DOAJ

【 摘 要 】

Radioactive-iodine (RAI) therapy is the mainstay for patients with recurrent and metastatic thyroid cancer. However, many patients exhibit dedifferentiation characteristics along with lack of sodium iodide symporter (NIS) functionality, low expression of thyroid-specific proteins, and poor RAI uptake, leading to poor prognosis. Previous studies have demonstrated the effect of GLI family zinc finger 1 (GLI1) inhibition on tumor growth and apoptosis. In this study, we investigated the role of GLI1 in the context of redifferentiation and improvement in the efficacy of RAI therapy for thyroid cancer. We evaluated GLI1 expression in several thyroid cancer cell lines and selected TPC-1 and SW1736 cell lines showing the high expression of GLI. We performed GLI1 knockdown and evaluated the changes of thyroid-specific proteins expression, RAI uptake and I-131-mediated cytotoxicity. The effect of GANT61 (GLI1 inhibitor) on endogenous NIS expression was also assessed. Endogenous NIS expression upregulated by inhibiting GLI1, in addition, increased expression level in plasma membrane. Also, GLI1 knockdown increased expression of thyroid-specific proteins. Restoration of thyroid-specific proteins increased RAI uptake and I-131-mediated cytotoxic effect. Treatment with GANT61 also increased expression of endogenous NIS. Targeting GLI1 can be a potential strategy with redifferentiation for restoring RAI avidity in dedifferentiated thyroid cancers.

【 授权许可】

Unknown